|
PD-L1 mRNA expression in patients with resectable gastric cancer and adenocarcinoma of the oesophago-gastric junction undergoing perioperative chemotherapy: Results from the FLOT4 phase III trial of the AIO. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Baxalta (Inst); Lilly (Inst); Merck (Inst) |
Research Funding - Sanofi |
Travel, Accommodations, Expenses - BMS Brazil; Merck |
|
|
Honoraria - Pfizer; Roche |
Consulting or Advisory Role - BMS Brazil; Lilly (Inst); MSD; Nordic Drugs; Roche; Taiho Pharmaceutical (Inst) |
Research Funding - Nordic Drugs (Inst); Taiho Pharmaceutical (Inst) |
Travel, Accommodations, Expenses - Amgen; BMS Brazil; Celgene |
|
|
Honoraria - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Novartis; Roche |
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst) |
Patents, Royalties, Other Intellectual Property - Highly sensitive method for mutation detection by PCR (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer (Inst); BMS Brazil (Inst); Celgene (Inst); Lilly (Inst); MSD (Inst); Shire (Inst) |
Speakers' Bureau - Lilly; MSD |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Lilly; Merck; Roche; SERVIER |
Speakers' Bureau - Celgene; Lilly; Nordic Bioscience; Roche |
Research Funding - Celgene; Hospira; Lilly; Medac; Novartis; Roche Pharma AG; Vifor Pharma |